Lisata files audited FY2020-2021 financials of acquired Cend Therapeutics

LISATA THERAPEUTICS, INC.

Audited financial statements of Cend for FY2020 and FY2021 filed as Exhibit 99.1.
Consent of independent auditor WithumSmith+Brown, PC filed as Exhibit 23.1.
This amendment fulfills the remaining financial statement requirements for the September 2022 merger.
No other changes were made to the initial Form 8-K reporting the merger completion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.